Gonzalez, Alba Castelo, Marcelo Marin, Karina Caballero, Henry Trujillo, Freddy [ION-SOLCA, Guayaquil (Ecuador)Įpidemiologic, comparative study of patients that entered to the Unit of Intensive Cares of the Quito Oncological Hospital SOLCA from January August 2005. There were determined the incidences of infections according to diagnostic, type of patient clinical, surgical or pediatric. The statistics tests used where percentages, Ji square, average, standard deviation and descriptive analysis. The clinical histories of all the patients of ICU were revised, the sheet of gathering data was filled. A number of 331 patients entered to the unit including post surgical, clinical with different diagnostic and pediatric surgical or clinical. Of these 19,63% (n: 64) were infected or were infected during their hospitalization. Their average age was of 51,33 years D S 21,9 the predominant sex was the feminine 60,9% (n:35).įor the analysis they were contained in surgical 21% (13), clinical 71% (46) and pediatrics 8% (5). The surgical patients where classified according to the surgery type in abdominal, thoracic, neurosurgery and other (head and neck or traumatology), significance didn't exist relating them with the surgery type, surgical time and infectious focus the mortality in these patients was of 21,4% (n:3). The clinical patients where chose in relation with the association or not of chemotherapy and the presence of the infectious focus founding a 39,14% (n:18) of infection in those patients that didn't receive chemotherapy and 60,86% (n:28) with infectious focuses in the patients that received chemotherapy the mortality in these patients were of 32,6%. Further informationĪlways consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.In the pediatrics patients with infectious focuses severe, antibiotic extensive therapy didn't settle down direct relationship with the infection. Consult with your healthcare professional before taking any medication. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. This means it is still under development and may contain inaccuracies. Important Notice: The international database is in BETA release. Uridine 5'-Triphosphate is reported as an ingredient of Nucleo Cmp Forte in the following countries: Ingredient matches for Nucleo Cmp Forte CytidineĬytidine is reported as an ingredient of Nucleo Cmp Forte in the following countries:Ĭytidine monophosphate (a derivative of Cytidine) is reported as an ingredient of Nucleo Cmp Forte in the following countries: Nucleo Cmp Forte may be available in the countries listed below.
0 Comments
Leave a Reply. |